Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves Use Of Fluarix Under An IND; GSK To Submit BLA In First Half ’05

Executive Summary

GlaxoSmithKline plans to establish a presence in the U.S. influenza vaccine market with a BLA submission for Fluarix in the first half of 2005
Advertisement

Related Content

GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy
GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy
IND Flu Vaccines Not Recommended For Routine Use, CDC Says
IND Flu Vaccines Not Recommended For Routine Use, CDC Says
Chiron Negotiating Fluvirin Distribution Agreements For 2005 Flu Season
FDA Vaccine Regs Should Allow Smoother Access To Foreign Products – Cmte.
Chiron Fluvirin Remediation Plan Includes Hiring Chief Microbiologist
FDA To Determine Flu Vaccine Suppliers For 2005-2006 Season In January
Flu Vaccine Shortage Shows Hazards Of Market Concentration – Sen. Leahy
Flu Vaccine Shortage Shows Hazards Of Market Concentration – Sen. Leahy
Advertisement
UsernamePublicRestriction

Register

PS045086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel